JP2017513859A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513859A5
JP2017513859A5 JP2016563034A JP2016563034A JP2017513859A5 JP 2017513859 A5 JP2017513859 A5 JP 2017513859A5 JP 2016563034 A JP2016563034 A JP 2016563034A JP 2016563034 A JP2016563034 A JP 2016563034A JP 2017513859 A5 JP2017513859 A5 JP 2017513859A5
Authority
JP
Japan
Prior art keywords
peg
conjugate
peg moiety
integrin
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016563034A
Other languages
English (en)
Japanese (ja)
Other versions
JP6789823B2 (ja
JP2017513859A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/025700 external-priority patent/WO2015160770A1/en
Publication of JP2017513859A publication Critical patent/JP2017513859A/ja
Publication of JP2017513859A5 publication Critical patent/JP2017513859A5/ja
Application granted granted Critical
Publication of JP6789823B2 publication Critical patent/JP6789823B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016563034A 2014-04-15 2015-04-14 両末端peg化インテグリン結合性ペプチドおよびその使用方法 Active JP6789823B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461979997P 2014-04-15 2014-04-15
US61/979,997 2014-04-15
PCT/US2015/025700 WO2015160770A1 (en) 2014-04-15 2015-04-14 Bi-terminal pegylated integrin-binding peptides and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2017513859A JP2017513859A (ja) 2017-06-01
JP2017513859A5 true JP2017513859A5 (enExample) 2018-05-31
JP6789823B2 JP6789823B2 (ja) 2020-11-25

Family

ID=54324485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016563034A Active JP6789823B2 (ja) 2014-04-15 2015-04-14 両末端peg化インテグリン結合性ペプチドおよびその使用方法

Country Status (8)

Country Link
US (3) US10919932B2 (enExample)
EP (1) EP3131566B1 (enExample)
JP (1) JP6789823B2 (enExample)
CN (1) CN106573031B (enExample)
AU (2) AU2015247833B2 (enExample)
CA (1) CA2945945C (enExample)
ES (1) ES2930029T3 (enExample)
WO (1) WO2015160770A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3131566B1 (en) * 2014-04-15 2022-10-05 The Regents of the University of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
WO2016134164A1 (en) * 2015-02-18 2016-08-25 Memorial Sloan Kettering Cancer Center Methods of enhancing cerenkov luminescence using nanoparticles, and compositions related thereto
KR20180100302A (ko) * 2015-10-23 2018-09-10 우니베르지태트 트벤테 인테그린 결합 펩티드 및 그의 용도
JP7081832B2 (ja) * 2016-06-13 2022-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア α(V)β(6)インテグリン結合ペプチドおよびその使用方法
US20190321310A1 (en) * 2016-06-16 2019-10-24 The University Of Liverpool Chemical composition
GB201613166D0 (en) 2016-07-29 2016-09-14 Vectura Ltd Polymer
JP7042053B2 (ja) * 2016-10-07 2022-03-25 国立大学法人東京工業大学 分岐型ヘテロ単分散ポリエチレングリコール、その製造方法、及びその結合体
CN109952376B (zh) * 2016-11-01 2023-09-05 箭头药业股份有限公司 αvβ6整联蛋白配体及其应用
GB201706472D0 (en) * 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
KR102762143B1 (ko) 2017-11-01 2025-02-07 애로우헤드 파마슈티컬스 인코포레이티드 인테그린 리간드 및 그의 용도
US20220211877A1 (en) * 2018-02-06 2022-07-07 Klinikum rechts der lsar der Techischen Universität München Compound for intraoperative molecular bioimaging, method of making the same, use thereof in intraoperative molecular bioimaging and surgical method comprising intraoperative molecular bioimaging
EP3846858A4 (en) 2018-09-07 2022-10-19 The Regents of the University of California Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
US11919972B2 (en) 2018-11-02 2024-03-05 Regeneron Pharmaceuticals, Inc. Peptide libraries with non-canonical amino acids
US12589161B2 (en) * 2019-07-10 2026-03-31 The University Of Hong Kong PEGylated synthetic KL4 peptide, compositions and methods thereof
CN110522923A (zh) * 2019-09-19 2019-12-03 四川大学 果糖和rgd肽共修饰的双重靶向三阴性乳腺癌的脂质材料
KR20220110729A (ko) * 2019-10-02 2022-08-09 서나오믹스, 인크. 뉴클레오시드 유사체를 포함하는 올리고뉴클레오티드
AU2020370362A1 (en) * 2019-10-25 2022-06-02 Children's Medical Center Corporation Computational design of alpha(v) beta (6) integrin binding proteins
WO2021226432A2 (en) * 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections
WO2022026867A1 (en) * 2020-07-31 2022-02-03 Cedars-Sinai Medical Center Glutamine as an anticancer therapy in solid tumors
US20230405129A1 (en) * 2020-10-20 2023-12-21 The Boad Of Regents Of The University Of Taxas System Proinflammatory prodrugs
WO2022098745A1 (en) * 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
JP2023552383A (ja) * 2020-12-04 2023-12-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ペプチド受容体放射性核種療法
BR112023020626A2 (pt) 2021-04-08 2023-12-19 Arrowhead Pharmaceuticals Inc Agentes de rnai para inibir a expressão do receptor para produtos finais de glicação avançada, composições dos mesmos e métodos de uso
WO2024263637A1 (en) 2023-06-20 2024-12-26 The Regents Of The University Of California Combination therapy with peptide receptor radionuclide and dna repair inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108386D0 (en) * 1991-04-19 1991-06-05 Agricultural Genetics Co Modified plant viruses as vectors
US5429133A (en) 1992-12-18 1995-07-04 Neoprobe Corporation Radiation responsive laparoscopic instrument
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
CA2439400A1 (en) 2001-02-26 2002-09-06 The Regents Of The University Of California Non-oligomerizing tandem fluorescent proteins
WO2002087497A2 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US7469107B2 (en) 2003-07-23 2008-12-23 Lexmark International, Inc. Method for providing imaging substance for use in an imaging device via a virtual replenishment
EP1756289B1 (en) 2004-05-24 2015-01-14 Midatech Ltd. Nanoparticles comprising rna ligands
GB0520068D0 (en) * 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
EP1935428A1 (en) * 2006-12-22 2008-06-25 Antisense Pharma GmbH Oligonucleotide-polymer conjugates
CA2694824A1 (en) * 2007-08-09 2009-02-12 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
WO2011123393A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
PL2455104T3 (pl) * 2010-11-19 2013-12-31 Univ Freiburg Bio-funkcjonalizowane reagujące na bodziec rozpuszczalne hydrożele PEG
CU23950B1 (es) * 2011-03-21 2013-10-29 Ct De Ingeniería Genética Y Biotecnología Péptidos cíclicos con actividad antineoplásica y antiangiogénica
US8895055B2 (en) 2011-12-21 2014-11-25 The Regents Of The University Of California Telodendrimer nanodiscs without apolipoprotein
EP3131566B1 (en) * 2014-04-15 2022-10-05 The Regents of the University of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
JP7081832B2 (ja) * 2016-06-13 2022-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア α(V)β(6)インテグリン結合ペプチドおよびその使用方法
EP3846858A4 (en) * 2018-09-07 2022-10-19 The Regents of the University of California Alpha(v)beta(6) integrin-binding peptides and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2019524871A5 (enExample)
JP6789823B2 (ja) 両末端peg化インテグリン結合性ペプチドおよびその使用方法
Juliano et al. Cell‐targeting and cell‐penetrating peptides for delivery of therapeutic and imaging agents
Li et al. Potent retro-inverso D-peptide for simultaneous targeting of angiogenic blood vasculature and tumor cells
ES2744225T3 (es) Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
Pooja et al. Bombesin receptors as potential targets for anticancer drug delivery and imaging
ES2901232T3 (es) Péptido diana de tumor maligno
Choksi et al. Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy
Feng et al. SPECT and near-infrared fluorescence imaging of breast cancer with a neuropilin-1-targeting peptide
CN104262460A (zh) 一种靶向人乳腺癌细胞的多肽及其应用
Ruoslahti Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier
Rizvi et al. Engineering peptide drug therapeutics through chemical conjugation and implication in clinics
JP5721140B2 (ja) 新生血管に対する標的化剤
Ciobanasu Peptides-based therapy and diagnosis. Strategies for non-invasive therapies in cancer
Guo et al. Peptides for diagnosis and treatment of ovarian cancer
Su et al. Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier
US12485191B2 (en) Radiopharmaceuticals and methods of use thereof
US20180360755A1 (en) Target-specific delivery of therapeutic agents
Okarvi et al. Preparation and evaluation of the tumor-specific antigen-derived synthetic mucin 1 peptide: A potential candidate for the targeting of breast carcinoma
CN108697756A (zh) Her2肽试剂和方法
CN113784735A (zh) 诊断肺癌的方法
Alshehri et al. In Vitro Evaluation and Biodistribution Studies of HPMA Copolymers Targeting the Gastrin Releasing Peptide Receptor in Prostate Cancer: Alshehri, Fan, Zhang and Garrison
JPWO2017086090A1 (ja) 膵癌に特異的な集積性を有するペプチド及びその使用
Guan et al. Targeting osteosarcoma vasculature with peptide obtained by phage display
Hendrikx et al. Use of Cyclic Backbone NGR‐Based SPECT to Increase Efficacy of Postmyocardial Infarction Angiogenesis Imaging